A+ R A-

Therapeutics in WM: Monoclonal Antibodies

Please select from the following list of abstracts, representing presentations given at Athens 2002 (IWWM-2) Session 6:

Combination Therapy with Rituximab and fludarabine is highly active in Waldenstrom's Macroglobulinemia. Steven Treon, Parveen Wasi, Christos Emmanouilides, Staley Frankel, Eva Kimby, Andrew Lister, Pierre Morel, Abigail Kelliher, Andrew Branagan, Frederick Preffer, Kenneth Anderson.

Pre-therapy serum IgM levels predict clinical response to extended rituximab in Waldenstrom's macroglobulinemia. Steven Treon, Christos Emmanouilides, Eva Kimby, Andrew Branagan, Constatine Mitsiades, Kenneth Anderson, and Stanley Frankel.

Polymorphisms in Fc gamma RIIIa (CD16) receptor expression are associated with clinical response to Ritucimab in Waldenstrom's macroglobulinemia. Steven Treon, Edward Fos, Mark Hansen, Sigitas Verselis, Andrew Branagan, Nikolaos Touroutoglou, David Maloney, Stanely Frankel, Menneth Anderson, Christos Emmmanouilides, and Eva Kimby.

Enhancing Rituximab Efficacy with IFN-Alfa. Eva Kimby.

CD22 as a target for pssive immubotherapy. Alessandra Cesano.

In Vivo efficacy of anti-CD40 antibody for human B- cell lineage hematological malignancies. Iqbal Grewal.

Campath-1H for treatment of Waldenstrom's Maccroglobulinemia (WM). Peggy Crowley-Norwick, Fred Preffer, Abby Kelliher, and Steven treon.

New Monoclonal Antibodies for the Treatment of Waldenstrom's macroglobulinemia and Chronic lymphocytic leukemia. John Byrd.

Phase I study of Zevalin (Ibritumomab Tiuxetan) in Waldenstrom's Macroglobulinemia (Lymphoplasmacytic lymphoma). C. Emmmanouilidies, P. Multani, S. Treon.